< Back to previous page

Publication

Gastric cancer

Journal Contribution - Journal Article

Gastric cancer is one of the leading causes of cancer-related death worldwide. Many patients have inoperable disease at diagnosis or have recurrent disease after resection with curative intent. Gastric cancer is separated anatomically into true gastric adenocarcinomas and gastro-oesophageal-junction adenocarcinomas, and histologically into diffuse and intestinal types. Gastric cancer should be treated by teams of experts from different disciplines. Surgery is the only curative treatment. For locally advanced disease, adjuvant or neoadjuvant therapy is usually implemented in combination with surgery. In metastatic disease, outcomes are poor, with median survival being around 1 year. Targeted therapies, such as trastuzumab, an antibody against HER2 (also known as ERBB2), and the VEGFR-2 antibody ramucirumab, have been introduced. In this Seminar, we present an update of the causes, classification, diagnosis, and treatment of gastric cancer.
Journal: LANCET
ISSN: 0140-6736
Issue: 10060
Volume: 388
Pages: 2654 - 2664
Publication year:2016
BOF-keylabel:yes
IOF-keylabel:yes
BOF-publication weight:10
CSS-citation score:4
Authors from:Higher Education
Accessibility:Closed